Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout Oct 21, 2025
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing Oct 01, 2025
Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference Sep 02, 2025
Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Aug 14, 2025
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Aug 12, 2025
